These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21385891

  • 1. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [Abstract] [Full Text] [Related]

  • 2. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):67-75. PubMed ID: 20486173
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.
    Cancer Res; 2005 May 01; 65(9):3868-76. PubMed ID: 15867386
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K.
    Clin Cancer Res; 2001 Jun 01; 7(6):1790-7. PubMed ID: 11410521
    [Abstract] [Full Text] [Related]

  • 9. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.
    Oncogene; 2011 Jun 16; 30(24):2730-40. PubMed ID: 21278796
    [Abstract] [Full Text] [Related]

  • 11. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.
    Cancer Res; 2003 Dec 15; 63(24):8912-21. PubMed ID: 14695208
    [Abstract] [Full Text] [Related]

  • 12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 13. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.
    Cancer Res; 2000 Nov 01; 60(21):6160-70. PubMed ID: 11085540
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
    Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M.
    Oncol Rep; 2005 Feb 01; 13(2):253-7. PubMed ID: 15643507
    [Abstract] [Full Text] [Related]

  • 15. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.
    Lung Cancer; 2008 May 01; 60(2):166-74. PubMed ID: 18006183
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
    Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P.
    Cancer; 2002 Oct 15; 95(8):1735-45. PubMed ID: 12365022
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma.
    Lipskar AM, Glick RD, Huang J, Fisher JC, DeVoti J, Pica R, Edelman M, Steinberg BM, Soffer SZ.
    J Pediatr Surg; 2009 Jun 15; 44(6):1139-46; discussion 1146-7. PubMed ID: 19524730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.